According to a new research report “Mechanistic Target of Rapamycin (mTOR) Inhibitors – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, mTOR inhibitors currently exhibits a proliferating pipeline with 20+ therapeutic candidates.

mTOR Inhibitors Pipeline Insights

Mechanistic target of rapamycin (mTOR) is a serine and threonine protein kinase that is considered as a target for immunosuppressive drug rapamycin and is present in two distinct complexes. The first, mTOR complex 1 (mTORC1), is comprised of mTOR, Raptor, GβL, and DEPTOR, and is inhibited by rapamycin. The mTORC1 is a master growth regulator that senses and integrates diverse nutritional and environmental cues, including growth factors, energy levels, cellular stress, and amino acids. The second complex, mTOR complex 2 (mTORC2), is comprised of mTOR, Rictor, GβL, Sin1, PRR5/Protor-1, and DEPTOR. The mTORC2 promotes cellular survival by activating Akt, regulates cytoskeletal dynamics by activating PKCα, and controls ion transport and growth via SGK1 phosphorylation.

mTOR is a precursor of many pathways related to cell growth and survival, hence dysregulation of this pathway causes unprecedent growth of malignant cells that leads to cancer. Kidney, breast, and neuroendocrine system are also affected by the dysregulation of this pathway. It has been found that inhibition of mTOR at the mTORC1 and mTORC2 complex can inhibit phosphorylation and translation of proteins, thus preventing further cell proliferation of malignant cells.

Some of the Food and Drug Administration (FDA) approved mTOR inhibitors include Rapamune, also known as rapamycin (Wyeth Pharmaceuticals Inc.), and Afinitor (Novartis AG).

Insights into Pipeline Segments

According to the research findings, majority of drug candidates in the pipeline are being developed for oral administration. It has been found that oral route of administration is easy to use, and ensures high level of patient satisfaction.

Positive Clinical Trial Results are Expected to Drive mTOR Inhibitors Pipeline

Companies that are involved in developing mTOR inhibitors have shown positive clinical results in the various phases of drug development. For instance, in July 2018, resTORbio Inc. announced positive topline result of phase IIb dose-ranging trial of RTB101, an mTOR inhibitor. The phase IIb study was successful in defining a dose, RTB101 10 mg once daily. The drug was observed to be well-tolerated that reduce the incidence of respiratory tract infections (RTIs) in elderly patients. Furthermore, in March 2019, resTORbio Inc. announced its plan to initiate phase III trial of RTB101 for the treatment of patients with RTIs.

Global Market for mTOR Inhibitors is Expected to Increase Statistically in the Next 10 years

As of 2019, rapamycin, also known sirolimus, and Afinitor (everolimus) are the FDA approved mTOR inhibitors. With the sale of these drugs and the emergence of products in pipeline project, the market for mTOR inhibitors is expected to witness significant growth in the coming years.

Browse report overview with detailed TOC on "Mechanistic Target of Rapamycin (mTOR) Inhibitors – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments" at:https://www.pharmaproff.com/report/mtor-inhibitors-therapeutics

Designations Granted by Regulatory Authorities to Accelerate the Drug Development Process

The FDA granted everolimus Orphan Drug designation for the treatment of tuberous sclerosis complex-related skin lesions in 2015. Therefore, with the increasing number of designation grants, the overall mTOR inhibitor therapeutics pipeline is expected to grow significantly in the upcoming years.

F. Hoffmann-La Roche Ltd., Novartis AG, Daiichi Sankyo Company Limited, Wyeth Pharmaceuticals Inc., Pfizer Inc., and resTORbio Inc. are some of the major players for mTOR inhibitors in the market.

mTOR Inhibitors Pipeline Analysis

• By Phase
• By Molecule Type
• By Route of Administration
• By Company

The report comprises detailed pipeline analysis of mTOR inhibitors under development. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the development of mTOR inhibitors. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to mTOR inhibitors.